A-317491

• CAT Number: I003655
• CAS Number: 475205-49-3
• Molecular Formula: C33H27NO8
• Molecular Weight: 565.57
• Purity: ≥95%
• Synonyms: 5-[(3-phenoxyphenyl)methyl-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid
• Target: P2X Receptor
• Solubility: DMSO: ≥ 47 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C33H27NO8/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41)/t29-/m0/s1
• InChIKey: VQGBOYBIENNKMI-LJAQVGFWSA-N
• SMILES: C1C[C@@H](C2=CC=CC=C2C1)N(CC3=CC(=CC=C3)OC4=CC=CC=C4)C(=O)C5=CC(=C(C=C5C(=O)O)C(=O)O)C(=O)O

A-317491（Cat No.:I003655）is a selective and potent antagonist of the P2X7 receptor, a type of purinergic receptor involved in inflammatory responses and immune cell activation. This receptor plays a key role in the release of pro-inflammatory cytokines and the activation of inflammasomes, which are implicated in various inflammatory diseases, including autoimmune disorders and neuroinflammation. By blocking P2X7 receptor activity, A-317491 has shown potential in reducing inflammation and alleviating pain. Preclinical studies suggest its utility in treating conditions such as rheumatoid arthritis and neurodegenerative diseases, though further clinical trials are necessary to evaluate its efficacy and safety.